NKTR Financial Facts
License, collaboration and other: 8.37MIncome (loss) from operations: -32.9M
See Full Income Statement
Deferred revenue, current portion: 14.1M
Total liabilities: 492.95M
See Full Balance Sheet
Nektar Therapeutics (NKTR ) Earnings
|
Expand Research on NKTR
| Next EPS Date | 11/5/26 | EPS Growth Rate | -212.4% |
|---|---|---|---|
| Average EPS % Beat Rate | +9.6% | Revenue Growth Rate | -12.6% |
| Average % Move 1-Wk after EPS | -2.1% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
11/5/26  |
Q326 | N/A | -$2.08 | N/A | N/A | $10.31M | N/A | N/A | N/A | ||
| 8/13/26 | Q226 | -$1.23 | -$2.00 | +$0.77 | $10.13M | $10.38M | N/A |  | | Details | |
| 8/6/26 |
Q226 | N/A | -$2.04 | N/A | N/A | $10.38M | N/A | N/A | N/A | ||
| 5/7/26 | Q126 | -$1.82 | $0.00 | -$1.82 | $10.9M | N/A | N/A | | | Details | |
| 3/12/26 | Q425 | -$1.78 | $0.00 | -$1.78 | $21.81M | N/A | N/A | | | Details | |
| 11/6/25 |
Q325 | N/A | -$0.19 | N/A | N/A | $9.84M | N/A | N/A | N/A | ||
| 11/6/25 | Q325 | $1.85 | $0.00 | +$1.85 | $11.79M | N/A | N/A | | | Details | |
| 8/7/25 | Q225 | -$2.78 | -$0.20 | -$2.58 | $11.17M | $9.74M | N/A | | | Details |
